Moderna (MRNA) Interest Expenses (2018 - 2026)

Moderna (MRNA) has 9 years of Interest Expenses data on file, last reported at $383.0 million in Q1 2026.

• On a quarterly basis, Interest Expenses fell 65.65% year-over-year to $383.0 million in Q1 2026; TTM through Mar 2026 was $383.0 million, a 65.65% decrease from a year earlier, with the FY2025 full-year figure at $213.0 million, down 93.09% from the prior year.
• Interest Expenses for Q1 2026 stood at $383.0 million, up from $81.0 million in the prior quarter.
• Over the last five years, Interest Expenses for MRNA reached as high as $3.1 billion in Q4 2024 and fell as low as $81.0 million in Q3 2025.
• Historically, Interest Expenses has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2024.
• Across the five-year window, Interest Expenses slumped 95.12% in 2022 and surged 1334.84% in 2023, its largest moves.
• Year by year, Interest Expenses stood at $155.0 million in 2022, then jumped by 1334.84% to $2.2 billion in 2023, then jumped by 38.67% to $3.1 billion in 2024, then plunged by 97.37% to $81.0 million in 2025, then soared by 372.84% to $383.0 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $383.0 million in Q1 2026, $81.0 million in Q3 2025, and $1.1 billion in Q2 2025.